{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T01:12:57Z","timestamp":1755825177527,"version":"3.44.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>This study sought to identify key prognostic factors in patients with hypertrophic cardiomyopathy (HCM) and heart failure with preserved ejection fraction (HFpEF), emphasizing the prognostic role of free triiodothyronine (FT3) levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>Research design and methods<\/jats:title><jats:p>This retrospective cohort study enrolled 992 HCM-HFpEF patients from two Chinese medical centers between 2009 and 2019, excluding those with thyroid-affecting medications or disorders. Data on demographic and clinical variables, including FT3, were analyzed using univariate and multivariate Cox regression, Kaplan\u2013Meier (KM) survival analysis, and restricted cubic spline (RCS) analysis to explore prognostic factors and FT3's nonlinear predictive value.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Age, atrial fibrillation, and NT-proBNP levels significantly influenced prognosis, while FT3 emerged as an independent predictor of all-cause mortality and cardiac transplantation (<jats:italic>P<\/jats:italic>\u2009&amp;lt;\u20090.001). Patients with lower FT3 exhibited poorer long-term outcomes, with RCS identifying a critical threshold of 2.885\u2005pg\/ml (<jats:italic>P<\/jats:italic>-non-linear\u2009&amp;lt;\u20090.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>FT3 is a robust prognostic marker in HCM-HFpEF patients, supporting its integration into risk stratification. Clinicians should monitor FT3 levels, though intervention efficacy requires further prospective validation.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2025.1546309","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T05:27:11Z","timestamp":1755754031000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic significance of FT3 levels in hypertrophic cardiomyopathy patients with HFpEF"],"prefix":"10.3389","volume":"12","author":[{"given":"Zhen-Yu","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Yuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Jie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Da","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fu-Shi","family":"Piao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangyu","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang-Tao","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng-song","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-Hou","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei-Hong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-Qing","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-jin","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12916-021-02219-7","article-title":"Identification of heart failure with preserved ejection fraction helps risk stratification for hypertrophic cardiomyopathy","volume":"20","author":"Liu","year":"2022","journal-title":"BMC Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s00392-023-02371-5","article-title":"Clinical characteristics and prognosis of patients with hypertrophic cardiomyopathy and heart failure with preserved ejection fraction","volume":"13","author":"Chen","year":"2024","journal-title":"Clin Res Cardiol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1002\/j.2040-4603.2016.tb00704.x","article-title":"Thyroid hormone and cardioprotection","volume":"6","author":"Gerdes","year":"2016","journal-title":"Compr Physiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1161\/01.ATV.0000233358.87583.01","article-title":"Thyroid hormone inhibits vascular remodeling through suppression of cAMP response element binding protein activity","volume":"26","author":"Fukuyama","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1097\/CM9.0000000000001505","article-title":"Assessment of causal association between thyroid function and lipid metabolism: a Mendelian randomization study","volume":"134","author":"Wang","year":"2021","journal-title":"Chin Med J (Engl)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"3926","DOI":"10.3760\/cma.j.issn.0366-6999.20130087","article-title":"Free triiodothyronine level indicates the degree of myocardial injury in patients with acute ST-elevation myocardial infarction","volume":"126","author":"Wang","year":"2013","journal-title":"Chin Med J (Engl)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1210\/jc.2017-02386","article-title":"Prognostic value of free triiodothyronine level in patients with hypertrophic obstructive cardiomyopathy","volume":"103","author":"Zhang","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3210","DOI":"10.1210\/jc.2014-4159","article-title":"Thyroid status, cardiac function, and mortality in patients with idiopathic dilated cardiomyopathy","volume":"100","author":"Wang","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s10741-008-9125-7","article-title":"Cardiac hypertrophy and thyroid hormone signaling","volume":"15","author":"Dillmann","year":"2010","journal-title":"Heart Fail Rev"},{"key":"B10","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.vph.2009.11.008","article-title":"Signaling mechanisms in thyroid hormone-induced cardiac hypertrophy","volume":"52","author":"Ojamaa","year":"2010","journal-title":"Vascul Pharmacol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e212","DOI":"10.1016\/j.jacc.2011.06.011","article-title":"2011 ACCF\/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons","volume":"58","author":"Gersh","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur Heart J"},{"key":"B13","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jacc.2021.12.002","article-title":"Diagnosis and evaluation of hypertrophic cardiomyopathy: JACC state-of-the-art review","volume":"79","author":"Maron","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e1054","DOI":"10.1161\/CIR.0000000000000490","article-title":"Role of biomarkers for the prevention, assessment, and management of heart failure: a scientific statement from the American Heart Association","volume":"135","author":"Chow","year":"2017","journal-title":"Circulation"},{"key":"B15","doi-asserted-by":"publisher","first-page":"11957","DOI":"10.1038\/s41598-017-12289-4","article-title":"Survival and prognostic factors in hypertrophic cardiomyopathy: a meta-analysis","volume":"7","author":"Liu","year":"2017","journal-title":"Sci Rep"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1136\/heartjnl-2019-316219","article-title":"Impact of atrial fibrillation in patients with heart failure and reduced, mid-range or preserved ejection fraction","volume":"106","author":"Son","year":"2020","journal-title":"Heart"},{"key":"B17","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1159\/000517618","article-title":"Gender-related differences in hypertrophic cardiomyopathy: a systematic review and meta-analysis","volume":"9","author":"Trongtorsak","year":"2021","journal-title":"Pulse (Basel)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1093\/eurheartj\/eht070","article-title":"Relation between serum N-terminal pro-brain natriuretic peptide and prognosis in patients with hypertrophic cardiomyopathy","volume":"34","author":"Coats","year":"2013","journal-title":"Eur Heart J"},{"key":"B19","doi-asserted-by":"publisher","first-page":"102155","DOI":"10.1016\/j.cpcardiol.2023.102155","article-title":"HFpEF: new biomarkers and their diagnostic and prognostic value","volume":"49","author":"Parveen Shaik","year":"2024","journal-title":"Curr Probl Cardiol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"617705","DOI":"10.3389\/fcvm.2020.617705","article-title":"Gender-related differences in heart failure biomarkers","volume":"7","author":"Cediel","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1007\/s11739-020-02582-y","article-title":"Prognostic role of hypothyroidism and low free-triiodothyronine levels in patients hospitalized with acute heart failure","volume":"16","author":"De Matteis","year":"2021","journal-title":"Intern Emerg Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.cardfail.2019.01.007","article-title":"Low T3 syndrome is associated with high mortality in hospitalized patients with heart failure","volume":"25","author":"Sato","year":"2019","journal-title":"J Card Fail"},{"key":"B23","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.amjmed.2014.03.009","article-title":"Thyroid and the heart","volume":"127","author":"Grais","year":"2014","journal-title":"Am J Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1161\/CIRCULATIONAHA.118.036859","article-title":"Thyroid and cardiovascular disease research agenda for enhancing knowledge, prevention, and treatment","volume":"139","author":"Cappola","year":"2019","journal-title":"Circulation"},{"key":"B25","doi-asserted-by":"publisher","first-page":"606931","DOI":"10.3389\/fphys.2021.606931","article-title":"Thyroid hormone plays an important role in cardiac function: from bench to bedside","volume":"12","author":"Yamakawa","year":"2021","journal-title":"Front Physiol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s10741-016-9556-5","article-title":"Thyroid hormones and heart failure","volume":"21","author":"Martinez","year":"2016","journal-title":"Heart Fail Rev"},{"key":"B27","doi-asserted-by":"publisher","first-page":"373","DOI":"10.4330\/wjc.v12.i8.373","article-title":"Sympathetic nervous system activation and heart failure: current state of evidence and the pathophysiology in the light of novel biomarkers","volume":"12","author":"Borovac","year":"2020","journal-title":"World J Cardiol"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1546309\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T05:27:11Z","timestamp":1755754031000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1546309\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":27,"alternative-id":["10.3389\/fcvm.2025.1546309"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2025.1546309","relation":{},"ISSN":["2297-055X"],"issn-type":[{"type":"electronic","value":"2297-055X"}],"subject":[],"published":{"date-parts":[[2025,8,21]]},"article-number":"1546309"}}